UBX

Unity Biotechnology, Inc. (UBX) | Rumor.io

Unity Biotechnology

UBX

Attention (50-day avg)0%

Attention rank (50-day avg)#4,809

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about UBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 1

$UBX is being shorted and is expected to delist, with some traders targeting a price of $0.20.
The company has more debt than cash and is being accused of scamming investors, with some traders predicting a further decline in price.
There is a potential short trade opportunity with $UBX, with some traders expecting the price to reach $0.13 or lower.

Generated by AI

Sentiment

Of the messages about UBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +12.37
Bearish	—	—	—	0% -12.37

Bullish· Mar 24

$UBX has significant potential for further growth, with some believing it could outperform other assets like $TRIA and $TEL.
Accumulating $UBX at current prices is considered a no-brainer for long-term investors.
$UBX is expected to follow in the footsteps of $POLX, which has been a successful investment, and could experience similar growth.

Bearish· Nov 2

The company's market capitalization has decreased significantly, with a current value of $37 million, down from $45 million raised in August, and the net asset value is valued at $7 million by the market.
The CEO's actions have led to a 97% destruction of the share price, and he is about to dilute the company further, potentially increasing the share outstanding by 150%, which could be a massive fraud against investors.
The company's pipeline, valued at $100 million, is priced at zero by the market, and the CEO is about to sell shares at one-third of the price from two months ago, which could be considered theft.

Generated by AI

Topics

Of the messages about UBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Analysts· Aug 18

Mizuho downgraded Unity Biotechnology to Neutral, while Citigroup and Morgan Stanley also downgraded the stock to Neutral and Equal Weight, respectively.
Morgan Stanley and Citigroup downgraded Unity Biotechnology to Equal Weight and Neutral, respectively, with price targets of $5.00 and $4.00.
Goldman Sachs lowered its target price for Unity Biotechnology to $4.00, maintaining a Neutral rating.

Announcements· Mar 28

$UBX Unity Biotechnology, Inc. has a strong chance of good results from its UBX1325 DME data, with a stronger efficacy observed in DME compared to current UBX1325 AMD results.
HC Wainwright & Co. reiterates a Buy rating for $UBX with a $10 price target, seeing 435% upside potential.
There is no specific announcement from $UBX, but several other companies announce financial results and patents, including Silo Pharma filing a patent for treatment of fibromyalgia.

Technical Analysis· Aug 12

$UBX is expected to be bullish as long as the VWAP holds, with potential dip buys and support in the $1.30-$1.40 zone.
An ascending triangle pattern on $UBX is forming, with the stock needing to hold the uptrend to squeeze and potentially breaking above $1.83 for a move to $2.
$UBX is testing its daily 200ema, with a strong close above the 10 and 20ema/5min with volume needed to show strength and potentially break above $1.46 to clear the 50ma.

Generated by AI

Community

Of the messages about UBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	1.45%
Newcomers	—	—	—	98.55%

Regulars· Apr 24

Unity Biotechnology's UBX1325 shows a favorable safety and tolerability profile in the Phase 2 BEHOLD study for patients with Diabetic Macular Edema.
The company will host a program update on the BEHOLD study, which will be reviewed during an investor call with a retinal expert.
The study's 48-week results are announced, marking a positive development for Unity Biotechnology's lead candidate in the treatment of Diabetic Macular Edema.

Newcomers· Mar 28

Many newcomers are excited about Silo Pharma's announcement of a patent filing for a treatment of fibromyalgia, which they believe could be a game-changer in the medical field.
Some users are comparing Silo Pharma's announcement to Unity Biotechnology's (UBX) own pipeline, speculating that UBX's focus on senolytic therapy could be a potential game-changer in the fight against age-related diseases.
Newcomers are also noting the similarities between Silo Pharma's treatment of fibromyalgia and Unity Biotechnology's (UBX) focus on developing treatments for age-related diseases, sparking hopes that UBX's pipeline could lead to breakthroughs in the medical field.

Generated by AI

News

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...

1mo agoBarchart.com

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing...

1mo agoBarchart.com

MBX Biosciences names Steve Hoerter as CEO, Kent Hawryluk steps down

2mo agoInvesting.com

Also Discussed

Investors talking about UBX also mention

#	Name	Attention
1	TE Connectivity plcTEL	0%new
2	Baxter International IncBAX	0%0
3	Vera Bradley Inc.VRA	0%0
4	Cohen & Steers Inc.CNS	0%0
5	TRTL - TortoiseEcofin Acquisition Corp. III	——
6	Cornerstone Building Brands IncCNR	0%new
7	QuickLogic CorporationQUIK	0%0
8	DAG - DB Agriculture Double Long ETN	——
9	Pro-Dex Inc.PDEX	0%0
10	BlackRock Municipal 2030 Target Term TrustBTT	0%0